Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease

Thrombosis and Haemostasis

Volumn 115, Issue 4, 2016, Pages 738-751

  He, Zhangxiu ^a,b   Si, Yu ^a,b   Jiang, Tao ^a   Ma, Ruishuang ^a,b   Zhang, Yan ^a   Cao, Muhua ^a,b   Li, Tao ^a   Yao, Zhipeng ^a   Zhao, Lu ^a   Fang, Shaohong ^b   Yu, Bo ^a,b   Dong, Zengxiang ^a   Thatte, Hemant S ^c   Bi, Yayan ^a   Kou, Junjie ^a   Yang, Shufen ^b   Piao, Daxun ^a   Hao, Lirong ^a   Zhou, Jin ^a   Shi, Jialan ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

IBD hypercoagulable disorders; Neutrophil extracellular traps; Phosphatidylserine; Procoagulant activity

Indexed keywords

BLOOD CLOTTING FACTOR 10A; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; LACTADHERIN; LEUKOCYTE ELASTASE; PHOSPHATIDYLSERINE; PROCOAGULANT; THROMBIN; TUMOR NECROSIS FACTOR; BLOOD CLOTTING FACTOR 5A; DEOXYRIBONUCLEASE I; FIBRIN; MEMBRANE ANTIGEN; MFGE8 PROTEIN, HUMAN; MILK PROTEIN; PROTEIN BINDING;

ARTICLE; BLOOD CLOTTING TIME; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EXTRACELLULAR TRAP; FIBRIN FORMATION; FLOW CYTOMETRY; HUMAN; HYPERCOAGULABILITY; IMMUNOFLUORESCENCE; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE ADHERENCE INHIBITION; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS; ADULT; AGED; BLOOD; BLOOD CLOTTING; CELL CULTURE; DRUG EFFECTS; FEMALE; MALE; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; THROMBOPHILIA;

ADULT; AGED; ANTIGENS, SURFACE; BLOOD COAGULATION; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; DEOXYRIBONUCLEASE I; EXTRACELLULAR TRAPS; FACTOR VA; FACTOR XA; FEMALE; FIBRIN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MILK PROTEINS; PHOSPHATIDYLSERINES; PROTEIN BINDING; THROMBOPHILIA;

EID: 84964735366     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-09-0710     Document Type: Article

References (54)

1. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657–663.
2. Tan VP, Chung A, Yan BP, et al. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28: 1095–1113.
3. Twig G, Zandman-Goddard G, Szyper-Kravitz M, et al. Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann NY Acad Sci 2005; 1051: 166–173.
4. Deutschmann A, Schlagenhauf A, Leschnik B, et al. Increased procoagulant function of microparticles in pediatric inflammatory bowel disease: role in increased thrombin generation. J Pediatr Gastroenterol Nutr 2013; 56: 401–407.
5. Scaldaferri F, Sans M, Vetrano S, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007; 117: 1951–1960.
6. Undas A, Owczarek D, Gissel M, et al. Activated factor XI and tissue factor in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1447–1478.
7. Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 1183–1188.
8. Smith CJ, Haire WD, Kaufman SS, et al. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91: 1221–1225.
9. Owczarek D, Cibor D, Salapa K, et al. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Inflamm Bowel Dis 2013; 19: 2616–2624.
10. Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost 2012; 107: 681–689.
11. Tan X, Shi J, Fu Y, et al. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost 2013; 109: 1025–1032.
12. Trappenburg MC, van Schilfgaarde M, Marchetti M, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94: 911–918.
13. Morel O, Jesel L, Freyssinet JM, et al. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 15–26.
14. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121–1132.
15. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594–2604.
16. Yan SL, Russell J, Granger DN. Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis 2014; 20: 353–362.
17. Yoshida H, Granger DN. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis 2009; 15: 1245–1255.
18. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532–1535.
19. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768–2776.
20. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463–469.
21. Bennike TB, Carlsen TG, Ellingsen T, et al. Neutrophil extracellular traps in ulcerative Colitis: A proteome analysis of intestinal biopsies. Inflamm Bowel Dis 2015; 21: 2052–2067.
22. Yan SL, Russell J, Harris NR, et al. Platelet abnormalities during colonic inflammation. Inflamm Bowel Dis 2013; 19: 1245–1253.
23. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174–186.
24. Campbell RA, Overmyer KA, Selzman CH, et al. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114: 4886–4896.
25. Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014; 111: 625–633.
26. Murdoch T, O’Donnell S, Silverberg MS, et al. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015; 29: 203–208.
27. Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm 2014; 2014: 325129.
28. Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of anti-proteinase 3 antineutrophil Cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013; 45: 109–116.
29. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623–625.
30. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Pes 2007; 149173–149186.
31. Allocca M, Fiorino G, Vermeire S, et al. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Rev Clin Immunol 2014; 10: 885–895.
32. Collins CE, Cahill MR, Newland AC, et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840–845.
33. Zilberman L, Rogowski O, Rozenblat M, et al. Inflammation-related erythrocyte aggregation in patients with inflammatory bowel disease. Dig Dis Sci 2005; 50: 677–683.
34. Vowinkel T, Wood KC, Stokes KY, et al. Mechanisms of platelet and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1054-G1060.
35. Leonetti D, Reimund JM, Tesse A, et al. Circulating microparticles from Crohn’s disease patients cause endothelial and vascular dysfunctions. PLoS One 2013; 8: e73088.
36. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membranebinding C2 domain of human coagulation factor V. Nature 1999; 402: 434–439.
37. Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. Blood 2003; 101: 2628–2636.
38. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887–896.
39. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880–15885.
40. Malickova K, Duricova D, Bortlik M, et al. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Autoimmune Dis 2011; 2011: 945861–945865.
41. Jimenez-Alcazar M, Napirei M, Panda R, et al. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J Thromb Haemost 2015; 13: 732–742.
42. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136–144.
43. Cooper PR, Palmer LJ, Chapple IL. Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe? Periodontology 2000 2013; 63: 165–197.
44. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729–1737.
45. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297–1301.
46. Hong Y, Eleftheriou D, Hussain AA, et al. Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol 2012; 23: 49–62.
47. Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? Trends Pharmacol Sci 2009; 30: 8–16.
48. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 2002; 161: 1903–1915.
49. Vergnolle N, Cellars L, Mencarelli A, et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004; 114: 1444–1456.
50. Semeraro F, Ammollo CT, Esmon NL, et al. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. J Thromb Haemost 2014; 12: 1697–1702.
51. Carty E, Rampton DS, Schneider H, et al. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn’s disease. Aliment Pharmacol Ther 2001; 15: 1323–1329.
52. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188–9192.
53. Davis JC, Jr., Manzi S, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 1999; 8: 68–76.
54. Papayannopoulos V, Staab D, Zychlinsky A. Neutrophil elastase enhances sputum solubilisation in cystic fibrosis patients receiving DNase therapy. PLoS One 2011; 6: e28526.